Molina healthcare inc（MOH.US AI Earnings Summary）
MOH AI Earnings Summary (In-Depth)
2026 Q3
Core Highlights
- Stock Price Reaction: Affected by a lowered 2027 premium outlook and cost pressures, pre-market shares fell as much as 1.95% after the earnings release. MOLINA HEALTHCARE INC (MOH) announced its financial results on October 22, 2026, before the market opened. The last closing price before the announcement was $214.90 on October 21. Although Q3 earnings met expectations, the stock fell by up to 1.95% pre-market (10/22 ET) as management lowered the preliminary 2027 premium revenue outlook and cited near-term medical cost pressures from a new Florida contract.
- Market Expectations: Adjusted EPS of $0.89 was in line with consensus, while premium revenue was approximately 5.2% below consensus. MOH's adjusted EPS this quarter was $0.89, precisely meeting the market expectation of $0.89. Premium revenue was approximately $10.5B, about 5.2% lower than the Wall Street consensus of $11.08B. The miss in premium revenue was primarily due to transition periods in government programs and membership adjustments in certain markets.
- Comparison to Previous Guidance: Some financial metrics met or exceeded guidance, but Marketplace MCR showed a significant lag. The consolidated Medical Care Ratio (MCR) for the quarter was 92.9%, slightly higher than the guidance of 92.6%. The adjusted G&A ratio of 6.3% and Medicaid MCR of 93% both performed better than guidance. However, the Marketplace MCR reached 92.5%, significantly higher than the company's expected 90%, primarily due to statewide risk score adjustments and minor impacts from program integrity measures.
- In One Sentence: MOH reaffirmed its full-year 2026 earnings guidance but lowered its 2027 premium outlook; the market responded with a pre-market price drop of up to 1.95%.
Quarterly Highlights
Medical Care Ratios for all three core businesses met internal expectations, demonstrating execution discipline in a high-cost environment.
Full-year adjusted EPS guidance remains unchanged, and this quarter's adjusted EPS met market consensus: Adjusted EPS for the quarter was $0.89, which is in line with the market consensus recorded by investing.com. The full-year 2026 adjusted EPS guidance is maintained at "at least $5.25," and premium revenue guidance remains at approximately $420B. Management has demonstrated stable execution capabilities in a high-cost environment.
Medicaid MCR outperformed the second-half expectations provided last quarter: This quarter's Medicaid MCR was 93%, lower than the 93.3% expected for the second half as stated in the previous earnings call, primarily benefiting from rate updates that partially offset upward pressure on medical costs. CFO Mark Keim noted that excluding the impact of the new Florida CMS contract, the Q4 Medicaid MCR is expected to improve by another 50 to 60 basis points compared to Q3, indicating that the core business rate cycle is gradually taking effect.
Strong performance in Medicare Dual Eligibles (Duals) business, with MCR better than last quarter's expectations: Medicare MCR for the quarter was 93%, lower than the 93.8% projected for the second half during the last call, driven primarily by Dual Eligible products (members eligible for both Medicare and Medicaid). The full-year Duals business is expected to contribute $1.25 per share with a pre-tax margin of 1.4%. CEO Joe Zubretsky stated that the Duals business is the core of MOH's Medicare strategy, and its 2026 performance lays the foundation for profit growth in 2027.
Smooth launch of the Florida CMS contract builds the foundation for profit over the next two years: The Florida CMS contract officially launched on October 1, taking on 115,000 child members with complex medical and behavioral health needs, representing an annualized premium revenue of $6B. CEO Joe Zubretsky described the "operational and clinical implementation as nearly flawless" and expects to reach break-even in 2027 and target margins by the second year of the contract. This contract turnaround is expected to contribute approximately $1.50 to EPS in 2027.
Preliminary 2027 EPS building blocks exceed $9.50, without accounting for potential Medicaid margin improvement: Management revealed the preliminary building blocks for 2027 EPS: starting with the 2026 full-year expectation of $5.25, adding approximately $4.00 in known embedded earnings (contributions from strategic initiatives), and another $0.75 from the Marketplace business returning to break-even. The total exceeds $9.50, and this figure does not yet include potential upside from Medicaid MCR improvements.
Adjusted G&A ratio better than full-year guidance, cost discipline continues: The adjusted General and Administrative (G&A) expense ratio for the quarter was 6.3%, lower than the full-year guidance of 6.4%. CFO Mark Keim pointed out that the Q4 G&A ratio is expected to drop further to below 6%, benefiting from operational leverage provided by the Florida CMS contract and rigorous cost management.
Robust capital structure with an ample cash position: At the end of the quarter, the parent company cash balance was approximately $600M, with operating cash flow for the first nine months at $629M and a net debt-to-capital ratio of 45%. CFO Mark Keim stated that the company has sufficient cash and financing channels to support ongoing growth plans and contract bidding.
RFP (Request for Proposal) pipeline progressing actively with a total opportunity scale of $90B: MOH has submitted bids in Missouri and Arizona, with the Indiana bid nearing completion and the Texas STAR Kids program bid pending review. CEO Joe Zubretsky stated that these active bids together represent approximately $26B in premium opportunities, part of the $90B total opportunity disclosed during Investor Day; management is confident in achieving favorable results.